Wockhardt Limited has announced a significant breakthrough with its investigational drug Zaynich™ (Zidebactam/Cefepime), which has successfully cured a complex case of meningitis caused by a pan-drug resistant super-bug, Pseudomonas, under compassionate use.
The case involved a 64-year-old patient with a history of Type 2 diabetes and hypertension, who had been battling pulmonary and meningeal tuberculosis for over a year. Following a spinal procedure, the patient developed bacterial meningitis due to the pan-drug resistant Pseudomonas, which could not be treated with conventional antibiotics. After initial treatment attempts with Ceftazidime/Avibactam, Aztreonam, and Meropenem failed, the medical team turned to Zidebactam/Cefepime as a last resort.
Administered over three weeks, the drug successfully eradicated the infection. The patient’s clinical condition improved rapidly, allowing them to be taken off mechanical ventilation and fully recover. This marks the first documented case of nosocomial meningitis caused by multidrug-resistant Pseudomonas to be treated with Zaynich™, highlighting the drug’s potential in combating complex, hard-to-treat infections.
Wockhardt’s Zaynich™ is currently undergoing a multi-national Phase III study and Phase II trials in India, aiming to become a globally approved treatment for multi-drug resistant infections.
